Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEMSYS: Pembrolizumab in Metastatic Melanoma
NCT03534635Phase 2Active, not recruiting
- Sponsor
- Lausanne University Hospital
- Start
- Jun 2018
- Primary completion
- Jun 2026
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in melanoma, sponsored by Lausanne University Hospital. Started Jun 2018; status: active, not recruiting.
02
Drugs
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT03534635.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03534635.